4.7 Review

Exploiting the placenta for nanoparticle-mediated drug delivery during pregnancy

Journal

ADVANCED DRUG DELIVERY REVIEWS
Volume 160, Issue -, Pages 244-261

Publisher

ELSEVIER
DOI: 10.1016/j.addr.2020.09.006

Keywords

Placenta; Drug delivery technologies; Nanoparticle; Pregnancy; Active targeting; Pre-eclampsia

Funding

  1. National Science Foundation (NSF) Graduate Research Fellowship [DGE 1845298]
  2. Graduate Education for Minorities (GEM) Fellowship
  3. University of Pennsylvania Fontaine Fellowship
  4. Hispanic Scholarship Fund (HSF)
  5. Burroughs Wellcome Fund Career Award at the Scientific Interface (CASI)
  6. US National Institutes of Health (NIH) Director's New Innovator Award [DP2 TR002776]
  7. American Cancer Society [129784-IRG-16-188-38-IRG]
  8. National Institutes of Health [NCI R01 CA241661, NCI R37 CA244911, NIDDK R01 DK123049]
  9. Abramson Cancer Center (ACC)-School of Engineering and Applied Sciences (SEAS) Discovery Grant [P30 CA016520]
  10. 2018 AACR-Bayer Innovation and Discovery Grant [18-80-44-MITC]
  11. NIH T32 multidisciplinary training grant [T32 HL007954]
  12. NIH F32 postdoctoral fellowship [F32CA243475]

Ask authors/readers for more resources

A major challenge to treating diseases during pregnancy is that small molecule therapeutics are transported through the placenta and incur toxicities to the developing fetus. The placenta is responsible for providing nutrients, removing waste, and protecting the fetus from toxic substances. Thus, the placenta acts as a biological barrier between the mother and fetus that can be exploited for drug delivery. Nanoparticle technologies provide the opportunity for safe drug delivery during pregnancy by controlling how therapeutics interact with the placenta. In this Review, we present nanoparticle drug delivery technologies specifically designed to exploit the placenta as a biological barrier to treat maternal, placental, or fetal diseases exclusively, while minimizing off-target toxicities. Further, we discuss opportunities, challenges, and future directions for implementing drug delivery technologies during pregnancy. (C) 2020 Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available